India, July 21 -- Shares of Helius Medical Technologies, Inc. (HSDT) soared 37% on Thursday, after the company announced positive clinical results from its PoNS Stroke Registrational Program (SRP).
The stock opened at $13.81, significantly above its prior close of $8.90. Trading volume was over 15.6 million shares, far above average daily volume of 153,000.
The neurotechnology firm focused on neuromodulation-based therapies said the PoNS device, a portable neuromodulation stimulator, demonstrated statistically significant improvements in gait and balance in chronic stroke patients.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The double-blind randomized clinical trial met its primary endpoint, wit...